Akebia Therapeutics vs Travere Therapeutics
AKBA and TVTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AKBA and TVTX compare
Travere Therapeutics is the larger company, worth 38 times as much as Akebia Therapeutics ($4.7B against $124M).
Travere Therapeutics grew revenue faster over the last twelve months (77.1% versus 7.5% for Akebia Therapeutics).
Travere Therapeutics keeps more of each dollar of sales as profit, with a net margin of −7.4% compared with −13.5% at Akebia Therapeutics.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AKBA | TVTX |
|---|---|---|
| Size and price | ||
| Market cap | $124M | $4.7B |
| Share price | $0.449 | $49.70 |
| Change, 1 year | −74.5% | 46.7% |
| Change, 5 years | −83.2% | 71.2% |
| Beta (5Y) | 1.05 | 1.95 |
| Employees | 194 | 497 |
| StockData Score | ||
| Total score | 6 | 6 |
| Valuation score | 0 | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 2 | 2 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.6× (better) | 7.9× |
| P/B | 5.0× (better) | 191× |
| EV/EBITDA | – | 192× |
| P/FCF | 3.1× | – |
| FCF yield | 32.4% | – |
| Fair value | – | $6.04 |
| Margin of safety | – | −723% |
| Growth | ||
| Revenue growth (TTM) | 7.5% | 77.1% (better) |
| Revenue growth, 5Y average | −4.3% | 19.9% (better) |
| Profitability | ||
| Gross margin | 79.6% | 98.6% (better) |
| Operating margin | −6.9% | −6.8% (better) |
| Net margin | −13.5% | −7.4% (better) |
| FCF margin | 18.4% | – |
| Return on equity | −109% (better) | −152% |
| Financial health | ||
| Debt / equity | 1.98 | – |
| Interest coverage | – | −4.3× |
| Current ratio | 1.43 | 4.05 (better) |
| Altman Z-score | −5.86 | 2.19 (better) |
| Piotroski F-score | 7 | 7 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 39.7% | 112% |
| Held by insiders | 2.9% | 1.6% |
| Insider net buying, 12 months | −$876K (better) | −$110M |
| Short interest, % of float | 10.1% | 10.3% |
Go deeper
- AKBA stock overview
- AKBA income statement
- AKBA valuation and score
- TVTX stock overview
- TVTX income statement
- TVTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.